EUVIMEDEUVIMED entdecken
Open Access

Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy

Filipe A Moura iD, Andrea Bellavia, David D Berg, Giorgio E M Melloni, Mark W Feinberg, Lawrence A Leiter, Erin A Bohula, David A Morrow, Benjamin A Scirica, Stephen D Wiviott, Marc S Sabatine iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Filipe A Moura und 10 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Weight Loss. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NHLBI NIH HHS, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To develop a clinical risk model to identify individuals at higher risk of developing new‐onset diabetes and who might benefit more from weight loss pharmacotherapy. Materials and Methods A total of 21 143 patients without type 2 diabetes at baseline from two TIMI clinical trials of stable cardiovascular patients were divided into a derivation (~2/3) and validation (~1/3) cohort. The primary outcome was new‐onset diabetes. Twenty‐seven candidate risk variables were considered, and variable selection was performed using multivariable Cox regression. The final model was evaluated for discrimination and calibration, and for its ability to identify patients who experienced a larger benefit from the weight loss medication lorcaserin in terms of risk of new‐onset diabetes.

Results

During a median (interquartile range) follow‐up of 2.3 (1.8–2.7) years, new‐onset diabetes occurred in 1013 patients (7.7%). The final model included five independent predictors (glycated haemoglobin, fasting glucose, age, body mass index, and triglycerides/high‐density lipoprotein). The clinical risk model showed good discrimination (Harrell's C‐indices 0.802, 95% confidence interval [CI] 0.788–0.817 and 0.807, 95% CI 0.788–0.826) in the derivation and validation cohorts. The calibration plot demonstrated adequate calibration (2.5‐year area under the curve was 81.2 [79.1–83.5]). While hazard ratios for new‐onset diabetes with a weight‐loss therapy were comparable across risk groups (annual risks of 5%), there was a sixfold gradient in absolute risk reduction from lowest to highest risk group ( p = 0.027).

Conclusions

The developed clinical risk model effectively predicts new‐onset diabetes, with potential implications for personalized patient care and therapeutic decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Weight LossHumansMaleFemaleMiddle AgedAgedRisk FactorsRisk AssessmentAnti-Obesity AgentsTreatment OutcomeBody Mass IndexObesity

Stichwörter der Autor:innen

antiobesity drugcardiovascular diseaseeffectivenessrandomised trialtype 2 diabetes

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Filipe A Moura, Marc S Sabatine

Förderung

  • American Heart Association-American Stroke Association
  • NHLBI NIH HHS
  • American Heart Association
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Moura, F. A., Bellavia, A., Berg, D. D., Melloni, G. E. M., Feinberg, M. W., Leiter, L. A., Bohula, E. A., Morrow, D. A., Scirica, B. A., Wiviott, S. D., & Sabatine, M. S. (2024). Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15798

Vancouver

Moura FA, Bellavia A, Berg DD, Melloni GEM, Feinberg MW, Leiter LA, et al. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15798

BibTeX
@article{Moura2024,
  author = {Moura, Filipe A and Bellavia, Andrea and Berg, David D and Melloni, Giorgio E M and Feinberg, Mark W and Leiter, Lawrence A and Bohula, Erin A and Morrow, David A and Scirica, Benjamin A and Wiviott, Stephen D and Sabatine, Marc S},
  title = {Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15798}
}
Kostenlos starten →